AstraZeneca and Eli Lilly and Co. said recently they will expand their present immuno-oncology collaboration to develop innovative combination therapy options for patients with solid tumors. Read More »
The U.S. Food and Drug Administration approved Strensiq (asfotase alfa) to treat perinatal, infantile and juvenile-onset hypophosphatasia (HPP), a rare, genetic, progressive, metabolic disease. Read More »
The U.S. Food and Drug Administration (FDA) recently approved Veltassa (patiromer for oral suspension) to treat patients with elevated levels of potassium in the blood, a condition known as hyperkalemia. Read More »
The U.S. Department of Health and Human Services Office of Inspector General said recently the federal Medicaid program could have realized savings if New York had applied medical loss ratio standards like those set in the Affordable Care Act (ACA). Read More »
Patients with high cholesterol are prescribed statins, but a recent study said about half of these patients will stop using the medication within the first year. Read More »
Cigna and Central Florida Affordable Care LLC announced on Thursday a collaboration to lower costs while improving health care and patient experience under Cigna’s accountable care organizations program called Cigna Collaborative Care. Read More »
A study of records at New York University's Langone Medical Center determined that too many patients being treated for severe acne are being left on ineffective antibiotics for too long before being prescribed isotretinoin (also known by its former brand name Accutane). Read More »
Track and Trace requirements scheduled to go into effect Sunday have been delayed until March 1, according to a Thursday announcement from the Food and Drug Administration (FDA). Read More »
Arena Pharmaceuticals Inc. has begun patient dosing in a Phase 1b multiple-ascending dose clinical trial of APD371, a selective agonist of the cannabinoid 2 (CB2) receptor. Read More »
Imlygic (talimogene laherparepvec) has become the first FDA-approved oncolytic virus therapy indicated for the treatment of melanoma lesions in the skin and lymph nodes. Read More »
PharmaEngine Inc. recently announced the U.S. Food and Drug Administration's (FDA) approval of Merimack's Onivyde (irinotecan liposome injection) in combination with fluorouracil (5-FU) and leucovorin (LV). Read More »
The American Society of Health-System Pharmacists (ASHP) recently published its annual compilation, ASHP Best Practices, featuring information such as quality policy positions, statements, guidelines, therapeutic position statements, and therapeutic and clinical practice guidelines for the pharmacy profession. Read More »
ClearPath Development Co. has partnered with Astellas Pharma Inc. to form a second vaccine company, Nosocomial Vaccine Corp. (NVC). Read More »
CVS Health's walk-in medical clinic, MinuteClinic, reached a milestone recently with the opening of its 1,000th location on Dupont Circle in Washington, D.C. Read More »
To help Medicare beneficiaries make better choices as they choose drug plans, pending regulatory guidance could increase transparency and accuracy of information on the Medicare Plan Finder website. Read More »
International litigation support provider UBIC Inc. has entered into a partnership with M3 Inc. to develop services through artificial intelligence (AI) technology to be used in the health care and pharmaceuticals industries. Read More »
The Food and Drug Administration (FDA) has expanded the approved uses of Yervoy (ipilimumab) to treat patients with Stage III melanoma. Read More »
The Food and Drug Administration (FDA) has approved Onivyde (irinotecan liposome injection), in combination with fluorouracil and leucovorin, for patients with advanced pancreatic cancer who have been treated previously with gemcitabine-based chemotherapy. Read More »
Walgreens Boots Alliance, Inc. and Rite Aid Corp. said Tuesday they have entered into a definitive agreement under which Walgreens will acquire all outstanding shares of Rite Aid.Under the agreement, Walgreens will acquire Rite Aid shares for $9 per share, for a total enterprise value of approximately $17.2 billion. Read More »
Walgreens announces purchase of Rite Aid in $17.2 billion deal. Read More »
Alerts Sign-up
